Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-22-005683
Filing Date
2022-04-21
Accepted
2022-04-21 07:03:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20220602xdefa14a.htm DEFA14A 18560
2 GRAPHIC tmb-20220602xdefa14a002.jpg GRAPHIC 129549
3 GRAPHIC tmb-20220602xdefa14a001.jpg GRAPHIC 212702
  Complete submission text file 0001558370-22-005683.txt   491118
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37581 | Film No.: 22839650
SIC: 2834 Pharmaceutical Preparations